Literature DB >> 23093699

MEN1 intragenic deletions may represent the most prevalent somatic event in sporadic primary hyperparathyroidism.

Maria Inês Alvelos1, João Vinagre, Elsa Fonseca, Eva Barbosa, José Teixeira-Gomes, Manuel Sobrinho-Simões, Paula Soares.   

Abstract

OBJECTIVE: Primary hyperparathyroidism (pHPT) is characterised by an inappropriate over production of parathyroid hormone and it is the most frequent pathological condition of the parathyroid glands. A minority of the cases belong to familial forms, but most of them are sporadic. The genetic alterations underlying the sporadic forms of pHPT remain poorly understood. The main goal of our study is to perform the molecular characterisation of a series of sporadic pHPT cases. DESIGN AND METHODS: We have studied matched blood and tumour from 24 patients with pHPT, who went to a medical appointment in Hospital Pedro Hispano. Informed consent was obtained from all individuals. The MEN1, RET and CDKN1B molecular study was carried out in the germline DNA by PCR/SSCP and direct sequencing. Parathyroid tumours were further analysed by the same methods for MEN1, CDKN1B and CTNNB1 genetic alterations. The multiplex ligation-dependent probe amplification technique enabled the evaluation of MEN1 gene deletions. Protein expression for menin, cyclin D1, parafibromin, p27(Kip1), β-catenin and Ki-67 was conducted by immunohistochemistry.
RESULTS: The study of parathyroid tumours detected two somatic MEN1 mutations (c.249_252delGTCT and c.115_163del49bp) and revealed the presence of MEN1 intragenic deletions in 54% (13/24) of the tumours. In RET and CDKN1B genes only previously described, non-pathogenic variants were found. Cyclin D1 protein was overexpressed in 13% (3/24) of tumours.
CONCLUSIONS: These results suggest that MEN1 alterations, remarkably intragenic deletions, may represent the most prevalent genetic alteration in sporadic parathyroid tumours.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23093699     DOI: 10.1530/EJE-12-0327

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  12 in total

1.  MEN1 mutations and potentially MEN1-targeting miRNAs are responsible for menin deficiency in sporadic and MEN1 syndrome-associated primary hyperparathyroidism.

Authors:  Vince Kornél Grolmusz; Katalin Borka; Annamária Kövesdi; Kinga Németh; Katalin Balogh; Csaba Dékány; András Kiss; Anna Szentpéteri; Beatrix Sármán; Anikó Somogyi; Éva Csajbók; Zsuzsanna Valkusz; Miklós Tóth; Péter Igaz; Károly Rácz; Attila Patócs
Journal:  Virchows Arch       Date:  2017-06-08       Impact factor: 4.064

Review 2.  Molecular genetics in primary hyperparathyroidism: the role of genetic tests in differential diagnosis, disease prevention strategy, and therapeutic planning. A 2017 update.

Authors:  Francesca Marini; Luisella Cianferotti; Francesca Giusti; Maria Luisa Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2017-05-30

Review 3.  MicroRNA deregulation in parathyroid tumours suggests an embryonic signature.

Authors:  C Verdelli; I Forno; V Vaira; S Corbetta
Journal:  J Endocrinol Invest       Date:  2015-01-11       Impact factor: 4.256

4.  Deletion of exons 1-3 of the MEN1 gene in a large Italian family causes the loss of menin expression.

Authors:  Maria Chiara Zatelli; Federico Tagliati; Mauro Di Ruvo; Emilie Castermans; Luigi Cavazzini; Adrian F Daly; Maria Rosaria Ambrosio; Albert Beckers; Ettore degli Uberti
Journal:  Fam Cancer       Date:  2014-06       Impact factor: 2.375

Review 5.  Intratumor heterogeneity in human parathyroid tumors.

Authors:  C Verdelli; G S Tavanti; S Corbetta
Journal:  Histol Histopathol       Date:  2020-05-29       Impact factor: 2.303

6.  MicroRNA-142-3p, a novel target of tumor suppressor menin, inhibits osteosarcoma cell proliferation by down-regulation of FASN.

Authors:  Yao-Qi Yang; Jin Qi; Jian-Qiang Xu; Ping Hao
Journal:  Tumour Biol       Date:  2014-07-18

7.  Loss of p27 expression is associated with MEN1 gene mutations in sporadic parathyroid adenomas.

Authors:  Simona Borsari; Elena Pardi; Natalia S Pellegata; Misu Lee; Federica Saponaro; Liborio Torregrossa; Fulvio Basolo; Elena Paltrinieri; Maria Chiara Zatelli; Gabriele Materazzi; Paolo Miccoli; Claudio Marcocci; Filomena Cetani
Journal:  Endocrine       Date:  2016-04-02       Impact factor: 3.633

Review 8.  Genomics and Epigenomics in Parathyroid Neoplasia: from Bench to Surgical Pathology Practice.

Authors:  C Christofer Juhlin; Lori A Erickson
Journal:  Endocr Pathol       Date:  2020-12-02       Impact factor: 3.943

9.  Comprehensive Analysis of MEN1 Mutations and Their Role in Cancer.

Authors:  Devi D Nelakurti; Amrit L Pappula; Swetha Rajasekaran; Wayne O Miles; Ruben C Petreaca
Journal:  Cancers (Basel)       Date:  2020-09-14       Impact factor: 6.639

10.  Molecular analysis of cyclin D1 modulators PRKN and FBX4 as candidate tumor suppressors in sporadic parathyroid adenomas.

Authors:  Kelly Brewer; Isabel Nip; Justin Bellizzi; Jessica Costa-Guda; Andrew Arnold
Journal:  Endocr Connect       Date:  2021-03       Impact factor: 3.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.